

Michael J Rieder

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8655047/publications.pdf>

Version: 2024-02-01

127
papers

5,029
citations

109321

35
h-index

95266

68
g-index

134
all docs

134
docs citations

134
times ranked

5327
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmacogenomic Prediction of Anthracycline-Induced Cardiotoxicity in Children. <i>Journal of Clinical Oncology</i> , 2012, 30, 1422-1428.	1.6	341
2	More Codeine Fatalities After Tonsillectomy in North American Children. <i>Pediatrics</i> , 2012, 129, e1343-e1347.	2.1	334
3	Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. <i>Nature Genetics</i> , 2009, 41, 1345-1349.	21.4	287
4	Regulation of cytokine and cytokine receptor expression by glucocorticoids. <i>Journal of Leukocyte Biology</i> , 1996, 60, 563-572.	3.3	277
5	A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer. <i>Nature Genetics</i> , 2015, 47, 1079-1084.	21.4	214
6	Reducing pain during vaccine injections: clinical practice guideline. <i>Cmaj</i> , 2015, 187, 975-982.	2.0	195
7	Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions. <i>Clinical Pharmacology and Therapeutics</i> , 1991, 49, 13-17.	4.7	193
8	Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 683-695.	2.4	188
9	Recommendations for <i>HLA-B*15:02</i> and <i>HLA-A*31:01</i> genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions. <i>Epilepsia</i> , 2014, 55, 496-506.	5.1	173
10	Hair cortisol analysis: An update on methodological considerations and clinical applications. <i>Clinical Biochemistry</i> , 2019, 63, 1-9.	1.9	143
11	Ontogeny of drug elimination by the human kidney. <i>Pediatric Nephrology</i> , 2006, 21, 160-168.	1.7	125
12	Effects of age on the serum concentration of β -1-acid glycoprotein and the binding of lidocaine in pediatric patients. <i>Clinical Pharmacology and Therapeutics</i> , 1989, 46, 219-225.	4.7	116
13	Sulfamethoxazole and Its Metabolite Nitroso Sulfamethoxazole Stimulate Dendritic Cell Costimulatory Signaling. <i>Journal of Immunology</i> , 2007, 178, 5533-5542.	0.8	111
14	Oral administration of morphine versus ibuprofen to manage postfracture pain in children: a randomized trial. <i>Cmaj</i> , 2014, 186, 1358-1363.	2.0	97
15	Genetic variants in <i>SLC22A17</i> and <i>SLC22A7</i> are associated with anthracycline-induced cardiotoxicity in children. <i>Pharmacogenomics</i> , 2015, 16, 1065-1076.	1.3	95
16	Exposure-based Interventions for the management of individuals with high levels of needle fear across the lifespan: a clinical practice guideline and call for further research. <i>Cognitive Behaviour Therapy</i> , 2016, 45, 217-235.	3.5	74
17	Haptenation of Sulfonamide Reactive Metabolites to Cellular Proteins. <i>Molecular Pharmacology</i> , 2002, 62, 1011-1026.	2.3	69
18	Cytotoxicity of sulfonamide reactive metabolites: apoptosis and selective toxicity of CD8 ⁺ cells by the hydroxylamine of sulfamethoxazole. <i>FASEB Journal</i> , 1999, 13, 1688-1698.	0.5	62

#	ARTICLE	IF	CITATIONS
19	Adverse Drug Reactions in Children: The Double-Edged Sword of Therapeutics. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 101, 725-735.	4.7	61
20	Palatability of Oral Antibiotics Among Children in an Urban Primary Care Center. <i>JAMA Pediatrics</i> , 2000, 154, 267.	3.0	60
21	Patch Testing for the Diagnosis of Anticonvulsant Hypersensitivity Syndrome. <i>Drug Safety</i> , 2009, 32, 391-408.	3.2	60
22	Twelve tips for enhancing student engagement. <i>Medical Teacher</i> , 2019, 41, 632-637.	1.8	58
23	Mechanisms of Unpredictable Adverse Drug Reactions. <i>Drug Safety</i> , 1994, 11, 196-212.	3.2	57
24	Pharmacogenomics of Vincristine-Induced Peripheral Neuropathy Implicates Pharmacokinetic and Inherited Neuropathy Genes. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 402-410.	4.7	56
25	An Algorithm to Detect Adverse Drug Reactions in the Neonatal Intensive Care Unit. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 87-95.	2.0	55
26	Intranasal ketamine for procedural sedation and analgesia in children: A systematic review. <i>PLoS ONE</i> , 2017, 12, e0173253.	2.5	55
27	Pharmacokinetic studies in children: recommendations for practice and research. <i>Archives of Disease in Childhood</i> , 2018, 103, archdischild-2017-314506.	1.9	55
28	The Risk of Adverse Pregnancy Outcome After First Trimester Exposure to H1 Antihistamines: A Systematic Review and Meta-Analysis. <i>Drug Safety</i> , 2017, 40, 121-132.	3.2	51
29	Assessment of the Palatability of Antistaphylococcal Antibiotics in Pediatric Volunteers. <i>Annals of Pharmacotherapy</i> , 1996, 30, 586-588.	1.9	47
30	Oral morphine versus ibuprofen administered at home for postoperative orthopedic pain in children: a randomized controlled trial. <i>Cmaj</i> , 2017, 189, E1252-E1258.	2.0	47
31	Attitudes and Practices Regarding Analgesia for Newborn Circumcision. <i>Pediatrics</i> , 1993, 92, 541-543.	2.1	45
32	Ifosfamide nephrotoxicity in children: a mechanistic base for pharmacological prevention. <i>Expert Opinion on Drug Safety</i> , 2009, 8, 155-168.	2.4	44
33	Toxicity of Sulfonamide-Reactive Metabolites in HIV-Infected, HTLV-Infected, and Noninfected Cells. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1995, 8, 134-140.	0.3	42
34	Serum sickness-like reaction to cefaclor: Lack of in vitro cross-reactivity with loracarbef*. <i>Clinical Pharmacology and Therapeutics</i> , 1998, 63, 686-693.	4.7	41
35	SJS/TEN 2019: From science to translation. <i>Journal of Dermatological Science</i> , 2020, 98, 2-12.	1.9	41
36	Drug Toxicity and Adverse Drug Reactions in Children - A Brief Historical Review. <i>Paediatric and Perinatal Drug Therapy</i> , 2002, 5, 12-18.	0.5	41

#	ARTICLE	IF	CITATIONS
37	Pretreatment with Glucocorticoids Enhances T-Cell Effector Function: Possible Implication for Immune Rebound Accompanying Glucocorticoid Withdrawal. <i>Cell Transplantation</i> , 1999, 8, 637-647.	2.5	37
38	What is the evidence for the safety and efficacy of using ketamine in children?. <i>Paediatrics and Child Health</i> , 2008, 13, 307-308.	0.6	36
39	Multiplicity of Glucocorticoid Action in Inhibiting Allograft Rejection. <i>Cell Transplantation</i> , 1998, 7, 511-523.	2.5	35
40	Increased Adverse Drug Reactions to Antimicrobials and Anticonvulsants in Patients with HIV Infection. <i>Annals of Pharmacotherapy</i> , 2006, 40, 1594-1601.	1.9	34
41	The cytotoxicity of clozapine metabolites: Implications for predicting clozapine-induced agranulocytosis. <i>Clinical Pharmacology and Therapeutics</i> , 1999, 65, 526-532.	4.7	33
42	In Vitro Testing for the Diagnosis of Anticonvulsant Hypersensitivity Syndrome. <i>Molecular Diagnosis and Therapy</i> , 2009, 13, 313-330.	3.8	31
43	If children ruled the pharmaceutical industry: The need for pediatric formulations. <i>Drug News and Perspectives</i> , 2010, 23, 458.	1.5	31
44	N-Acetylcysteine as a Novel Prophylactic Treatment for Ifosfamide-Induced Nephrotoxicity in Children: Translational Pharmacokinetics. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 55-64.	2.0	28
45	Assessment of the palatability of vehicles for activated charcoal in pediatric volunteers. <i>Pediatric Emergency Care</i> , 2002, 18, 19-21.	0.9	27
46	Palatability, adherence and prescribing patterns of antiretroviral drugs for children with human immunodeficiency virus infection in Canada. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 1246-1252.	1.9	27
47	Public Perceptions of Pharmacogenetics. <i>Pediatrics</i> , 2014, 133, e1258-e1267.	2.1	26
48	The Effect of Corrected Inflammation, Oxidative Stress and Endothelial Dysfunction on Fmd Levels in Patients with Selected Chronic Diseases: A Quasi-Experimental Study. <i>Scientific Reports</i> , 2020, 10, 9018.	3.3	26
49	Interventions for the treatment of decreased bone mineral density associated with HIV infection. <i>The Cochrane Library</i> , 2007, , CD005645.	2.8	24
50	Inhibition of Cytokine Production and Cytokine-Stimulated T-Cell Activation by FK506 (Tacrolimus)1. <i>Cell Transplantation</i> , 2001, 10, 615-623.	2.5	23
51	<i>In vitro</i> testing for diagnosis of idiosyncratic adverse drug reactions: Implications for pathophysiology. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 889-900.	2.4	23
52	New Ways to Detect Adverse Drug Reactions in Pediatrics. <i>Pediatric Clinics of North America</i> , 2012, 59, 1071-1092.	1.8	22
53	Pharmacogenomics and adverse drug reactions in children. <i>Frontiers in Genetics</i> , 2014, 5, 78.	2.3	22
54	Adverse Drug Reactions in Children: Pediatric Pharmacy and Drug Safety. <i>Journal of Pediatric Pharmacology and Therapeutics</i> , 2019, 24, 4-9.	0.5	22

#	ARTICLE	IF	CITATIONS
55	Predictive Value of the Lymphocyte Toxicity Assay in the Diagnosis of Drug Hypersensitivity Syndrome. <i>Molecular Diagnosis and Therapy</i> , 2010, 14, 317-322.	3.8	21
56	Design and conduct of early phase drug studies in children: challenges and opportunities. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 1308-1314.	2.4	21
57	Role of Oxidative Stress in Hypersensitivity Reactions to Sulfonamides. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 409-421.	2.0	21
58	Neuroblastoma after prenatal exposure to phenytoin: Cause and effect?. <i>Teratology</i> , 1989, 40, 157-162.	1.6	20
59	Adverse Drug Reactions Across the Age Continuum: Epidemiology, Diagnostic Challenges, Prevention, and Treatments. <i>Journal of Clinical Pharmacology</i> , 2018, 58, S36-S47.	2.0	20
60	Immunopharmacology and Adverse Drug Reactions. <i>Journal of Clinical Pharmacology</i> , 1993, 33, 316-323.	2.0	19
61	Immune mediation of hypersensitivity adverse drug reactions: implications for therapy. <i>Expert Opinion on Drug Safety</i> , 2009, 8, 331-343.	2.4	19
62	A Surveillance Method for the Early Identification of Idiosyncratic Adverse Drug Reactions. <i>Drug Safety</i> , 2008, 31, 169-180.	3.2	18
63	Improving paediatric medications: A prescription for Canadian children and youth. <i>Paediatrics and Child Health</i> , 2019, 24, 333-335.	0.6	18
64	Hypersensitivity of HIV-1-Infected Cells to Reactive Sulfonamide Metabolites Correlated to Expression of the HIV-1 Viral Protein Tat. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 314, 1218-1225.	2.5	17
65	Inhibition of cytokine production and interference in IL-2 receptor-mediated Jak-Stat signaling by the hydroxylamine metabolite of sulfamethoxazole. <i>FASEB Journal</i> , 2001, 15, 1855-1857.	0.5	14
66	The Predictive Value of the In Vitro Platelet Toxicity Assay (iPTA) for the Diagnosis of Hypersensitivity Reactions to Sulfonamides. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 626-632.	2.0	14
67	Risks and Benefits of Drugs Used in the Management of the Hyperactive Child. <i>Drug Safety</i> , 1993, 9, 38-50.	3.2	13
68	In Vitro Testing for Hypersensitivity-Mediated Adverse Drug Reactions: Challenges and Future Directions. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 90, 455-460.	4.7	13
69	Pharmacogenomic screening for anthracycline-induced cardiotoxicity in childhood cancer. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1143-1145.	2.4	13
70	Age- and Gender-Related Differences in Clinical Productivity Among Canadian Pediatricians. <i>Pediatrics</i> , 1990, 85, 144-149.	2.1	13
71	The In Vitro Platelet Toxicity Assay (iPTA): A Novel Approach for Assessment of Drug Hypersensitivity Syndrome. <i>Journal of Clinical Pharmacology</i> , 2011, 51, 428-435.	2.0	12
72	Rapid Resolution of Tacrolimus Intoxication-Induced AKI With a Corticosteroid and Phenytoin. <i>Annals of Pharmacotherapy</i> , 2014, 48, 1525-1528.	1.9	12

#	ARTICLE	IF	CITATIONS
73	Quality of life in children with adverse drug reactions: a narrative and systematic review. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 827-833.	2.4	12
74	Pharmacogenomics in Pediatric Oncology: Mitigating Adverse Drug Reactions While Preserving Efficacy. <i>Annual Review of Pharmacology and Toxicology</i> , 2021, 61, 679-699.	9.4	12
75	Pharmacogenomic testing in paediatrics: Clinical implementation strategies. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 4297-4310.	2.4	12
76	A palatability study of a flavored dexamethasone preparation versus prednisolone liquid in children. <i>Journal of Population Therapeutics and Clinical Pharmacology</i> , 2008, 15, e95-8.	1.9	12
77	Severe Generalized Bullous Fixed Drug Eruption Treated with Cyclosporine: A Case Report and Literature Review. <i>Case Reports in Dermatology</i> , 2021, 13, 154-163.	0.8	10
78	Paediatric pharmacotherapy and drug regulation: Moving past the therapeutic orphan. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 4250-4257.	2.4	10
79	Phenytoin activates Smad3 phosphorylation and periostin expression in drug-induced gingival enlargement. <i>Histology and Histopathology</i> , 2018, 33, 1287-1298.	0.7	10
80	How sweet it isn't: a new formulation of sodium phenylbutyrate and the challenge of palatability for medicines for children. <i>Archives of Disease in Childhood</i> , 2012, 97, 1080-1080.	1.9	8
81	Intraurethral Lidocaine for Urethral Catheterization in Children: A Randomized Controlled Trial. <i>Pediatrics</i> , 2015, 136, e879-e886.	2.1	8
82	Paediatric serum sickness-like reaction: A 10-year retrospective cohort study. <i>Paediatrics and Child Health</i> , 2021, 26, 428-435.	0.6	6
83	The trials and tribulations of doing drug research in children. <i>Cmaj</i> , 2003, 169, 1033-4.	2.0	6
84	Severe bullous hypersensitivity reactions after exposure to carbamazepine in a Han-Chinese child with a positive HLA-B*1502 and negative in vitro toxicity assays: evidence for different pathophysiological mechanisms. <i>Journal of Population Therapeutics and Clinical Pharmacology</i> , 2011, 18, e1-9.	1.4	6
85	HIV Tat potentiates cell toxicity in a T cell model for sulphamethoxazole-induced adverse drug reactions. <i>Virus Genes</i> , 2009, 38, 372-382.	1.6	5
86	Nifedipine and phenytoin induce matrix synthesis, but not proliferation, in intact human gingival connective tissue ex vivo. <i>Journal of Cell Communication and Signaling</i> , 2015, 9, 361-375.	3.4	5
87	Endogenous Glucocorticoid Response to Single-Dose Dexamethasone for Croup in Children. <i>Pediatric Emergency Care</i> , 2020, 36, 50-56.	0.9	5
88	Size and Taste Matters: Recent Progress in the Development of Age-Appropriate Medicines for Children. <i>Pharmaceutical Medicine</i> , 2018, 32, 21-30.	1.9	5
89	HIV-1 tat expression and sulphamethoxazole hydroxylamine mediated oxidative stress alter the disulfide proteome in Jurkat T cells. <i>Virology Journal</i> , 2018, 15, 82.	3.4	5
90	Regulatory approval for new pharmacogenomic tests: a comparative overview. <i>Food and Drug Law Journal</i> , 2011, 66, 1-24, i.	0.4	5

#	ARTICLE	IF	CITATIONS
91	The child with multiple short courses of steroid therapy. <i>Paediatrics and Child Health</i> , 2003, 8, 226-226.	0.6	4
92	Adverse drug reactions. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 613-614.	2.4	4
93	Pharmacy and pediatric drug therapy: The key to safe and effective treatment for children. <i>American Journal of Health-System Pharmacy</i> , 2019, 76, 1452-1453.	1.0	4
94	Pharmacogenomics in Children. <i>Methods in Molecular Biology</i> , 2014, 1175, 687-707.	0.9	4
95	Drug reaction with eosinophilia and systemic symptoms (DRESS): A tertiary care centre retrospective study. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 4134-4141.	2.4	4
96	DÃ©jÃ©vu all over Again: Adverse Reactions to Nonnucleoside Reverse Transcriptase Inhibitors. <i>Annals of Pharmacotherapy</i> , 2000, 34, 940-942.	1.9	3
97	Hypersensitivity adverse drug reactions in children: Pathophysiology and therapeutic implications. <i>Current Therapeutic Research</i> , 2001, 62, 913-929.	1.2	3
98	A supplementary home dose of oral ondansetron given in anticipation of recurrent emesis in paediatric acute gastroenteritis. <i>Paediatrics and Child Health</i> , 2014, 19, 107-108.	0.6	3
99	Do we prescribe medicines rationally?. <i>Archives of Disease in Childhood</i> , 2015, 100, 958-959.	1.9	3
100	Health-related quality of life in children with cutaneous adverse drug reactions. <i>Pediatric Dermatology</i> , 2017, 34, e341-e342.	0.9	3
101	Authorizing medical cannabis for children. <i>Paediatrics and Child Health</i> , 2020, 25, S14-S15.	0.6	3
102	Model Based Evaluation of Hypersensitivity Adverse Drug Reactions to Antimicrobial Agents in Children. <i>Frontiers in Pharmacology</i> , 2021, 12, 638881.	3.5	3
103	Time for a regulatory framework for pediatric medications in Canada. <i>Cmaj</i> , 2022, 194, E678-E680.	2.0	3
104	Prescription drug costs. <i>Paediatrics and Child Health</i> , 2004, 9, 569-570.	0.6	2
105	The CAM network â€œ Challenges and opportunities. <i>Paediatrics and Child Health</i> , 2005, 10, 201-202.	0.6	2
106	Is NSAID use in children associated with the risk of renal injury?. <i>Paediatrics and Child Health</i> , 2019, 24, 119-121.	0.6	2
107	Health-related quality of life among children who have had adverse drug reactions. <i>Paediatric and Perinatal Drug Therapy</i> , 2005, 6, 186-191.	0.5	2
108	Prescribing competency assessment for Canadian medical students: a pilot evaluation. <i>Canadian Medical Education Journal</i> , 2019, 10, e103-e110.	0.4	2

#	ARTICLE	IF	CITATIONS
109	Genetic markers of drug hypersensitivity in pediatrics: current state and promise. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 715-728.	3.1	2
110	Optimal Drug Therapy for Children. <i>Paediatric Drugs</i> , 2009, 11, 48-51.	3.1	1
111	Consider If You Will: Proton Pump Inhibitors in Children, Infections, and Precision Medicine. <i>Pediatrics</i> , 2019, 144, e20192544.	2.1	1
112	Not every white spot is vitiligo. <i>Paediatrics and Child Health</i> , 2022, 27, 1-3.	0.6	1
113	Idiosyncratic drug reactions and membranous glomerulopathy. <i>BMJ Case Reports</i> , 2017, 2017, bcr2016218496.	0.5	1
114	Key Potentially Inappropriate Drugs in Pediatrics: The KIDs List. <i>Journal of Pediatric Pharmacology and Therapeutics</i> , 2020, 25, 173-174.	0.5	1
115	Neither the "Devil's Lettuce" nor a "Miracle Cure": The Use of Medical Cannabis in the Care of Children and Youth. <i>Neuroethics</i> , 2022, 15, 1.	2.8	1
116	Child health care in Ukraine. <i>Paediatrics and Child Health</i> , 1997, 2, 337-341.	0.6	0
117	Ecstasy. <i>Paediatrics and Child Health</i> , 2002, 7, 71-72.	0.6	0
118	Better drug therapy for children: Time for action. <i>Paediatrics and Child Health</i> , 2003, 8, 210-212.	0.6	0
119	Baby boy blue " why is this newborn lethargic?. <i>Paediatrics and Child Health</i> , 2010, 15, 571-572.	0.6	0
120	Development of Drugs from Plants. <i>Advances in Botanical Research</i> , 2012, 62, 385-408.	1.1	0
121	Measuring oral bioavailability of tacrolimus. <i>Pediatric Transplantation</i> , 2014, 18, 656-657.	1.0	0
122	Exome sequencing pilot study in children with carbamazepine-induced serious skin reactions. <i>Clinical and Translational Allergy</i> , 2014, 4, P119.	3.2	0
123	Natural health product use in children: Common and important. <i>Paediatrics and Child Health</i> , 2015, 20, 10-10.	0.6	0
124	Cytoplasmic Distribution of HIV-1 Tat Sensitizes Jurkat T cells to Sulphamethoxazole-Hydroxylamine Induced Toxicity. <i>HIV Current Research</i> , 2016, 01, .	0.1	0
125	L'actualisation des médicaments à usage pédiatrique : une prescription pour les enfants et les adolescents canadiens. <i>Paediatrics and Child Health</i> , 2019, 24, 336-339.	0.6	0
126	Clinical Pharmacology and the Individualized Approach to Treatment. , 2015, , 187-201.		0

#	ARTICLE	IF	CITATIONS
127	Perspectives on interactions between paediatricians and the pharmaceutical industry. Paediatrics and Child Health, 2005, 10, 147-8.	0.6	0